 |
|
|
|
|
|
|
|
|
|
|
|
1 to 8 of 8 results |
|
 |
|
|
|
|
|
 |
|
|
|
|
Dokholyan N, Redler R. on PAPER: Vassall KA. et al., 2011, In this article, the authors address the contribution of mutant SOD1 stability loss and... 26 Jan 2011.
|
|
|
 |
|
|
Dokholyan N, Wilcox K. on NEWS: Focus on Aβ Fibrils: Targeting β-sheets and Foiling Them, By a high-throughput screen using >3,000 small molecules, the authors found... 23 Sep 2004.
|
|
|
|
|
|
Dokholyan N. on PAPER: Kammerer RA. et al., 2004, Comment by B. Edward Bondo and Nikolay V. Dokholyan
Kammerer et al. have developed a... 9 Mar 2004.
|
|
|
|
|
|
Dokholyan N, Khare S. on PAPER: Reixach N. et al., 2004, Reixach et al. study the aggregation and cytotoxicity of mutant and wild-type (WT)
forms of... 9 Mar 2004.
|
|
|
|
|
|
Dokholyan N, Khare S. on PAPER: Didonato M. et al., 2003, DiDonato and coworkers have studied the cysteine-independent aggregation of
two FALS-associated... 22 Sep 2003.
|
|
|
|
|
|
Bautz D, Dokholyan N. on PAPER: Laurine E. et al., 2003, By David Bautz and Nikolay Dokholyan. Laurine et al. study lithostathine, a protein that has... 22 Sep 2003.
|
|
|
|
|
|
Dokholyan N. on NEWS: Neuron Recognition Gone to Potts, A general problem in neuroanatomy arises from the difficulty to acquire sufficient positional... 20 Mar 2003.
|
|
|
|
|
|
Dokholyan N. on PAPER: Fonte V. et al., 2002, Fonte et al. study an intracellular aggregation of Aβ in the transgenic C. elegance... 25 Jul 2002.
|
|
|
|
|
|
|
1 to 8 of 8 results |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
The ALS Forum is a web-based collaborative effort to bring together valuable ALS-related resources for use by researchers worldwide in both academia and industry-based settings.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Should the FDA be allowed to use data from overseas clinical trials? |
|
|
|
|
|
|
|
|
|
|
|
Absolutely, we are running out of viable subjects in the U.S. |
|
|
|
|
|
|
 9 |
|
|
|
|
|
|
|
|
|
|
|
Yes, so long as the data is reliable |
|
|
|
|
|
|
31 |
|
|
|
|
|
|
|
|
|
|
|
No, the trials are not as rigorous |
|
|
|
|
|
|
3 |
|
|
|
|
|
|
|
|
|
|
|
No, the data should be repeated in the U.S. |
|
|
|
|
|
|
5 |
|
|
|
|
|
|
|
|
|
|
|
No, the drug sponsors are just trying to cut corners |
|
|
|
|
|
|
3 |
|
|
|
|
|
|
|
|
|
|
|
Responses: 51 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
Archived Polls |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
 Antibodies
Cell Lines
Collaborators
Papers
Research Participants
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Home
Check out our most recent Webinar: 
